Marijuana Dependence | Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
Marijuana Dependence research study
What is the primary objective of this study?
Recent studies have established the reliability, validity and time course of the cannabis withdrawal syndrome. This study will investigate the effects of combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. We predict that combined pharmacological treatment and cognitive-behavior therapy will help patients to abstain from using using marijuana and it will alleviate their marijuana withdrawal symptoms.
Who is eligible to participate?
Inclusion Criteria: - Men and women aged 20-45 - DSM IV criteria of marijuana dependence. Exclusion Criteria: - Other drug or alcohol dependence - Bipolar disorder, schizophrenia, major depression, suicidal ideation, psychotic symptoms or violent thoughts - Physical illness including hypothyroidism, neurological disease, severe anemia, and renal failure - Past severe side effects of SSRIs.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
AEscitalopram + cognitive-behavior treatment
BPlacebo + cognitive-behavior therapy
Start Date: December 2007
Completed Date: October 2008
Primary Outcome: Clean urine THC samples
Secondary Outcome: Questionnaire ratings of anxiety and depression and withdrawal symptoms
Study sponsors, principal investigator, and references
Principal Investigator: Miki Bloch, M.D
Lead Sponsor: Tel-Aviv Sourasky Medical Center